Esoguard
What is the EsoGuard® esophageal DNA test?
With ~90% sensitivity and ~99% negative predictive value at detecting Barrett's esophagus1,2,3 and esophageal adenocarcinoma,1,2 the EsoGuard test allows detection of these conditions in a simple office-based procedure without endoscopy.
The assay uses targeted next generation sequencing (NGS) to examine individual DNA molecules for the presence or absence of cytosine methylation at 31 different genomic locations.
Over 90% of Esophageal Adenocarcinoma patients never knew they had treatable Barrett's Esophagus4
Find Barrett's before it progresses
Barrett's esophagus (BE) is the only known precursor of esophageal cancer.5 Barrett's is related to gastroesophageal reflux disease (GERD) which can cause cells in the esophagus to change in an abnormal way that could lead to cancer.
BE itself doesn’t cause symptoms, so many people are unaware that they have the disease and therefore unaware of their risk of developing cancer.
How it Works
Cell Collection
Distal esophageal cells are sampled in a simple office-based procedure and sent to our laboratory.
Test
The EsoGuard Esophageal DNA Test assesses signature epigenetic changes indicative of BE and EAC using advanced molecular diagnostic techniques.
Results
The clinician receives a report with a positive or negative result indicating whether or not epigenetic changes consistent with BE/EAC were detected.
Who is at risk?
The risk of esophageal precancer is highest in patients with gastroesophageal reflux disease (GERD), age over 50, male, white race, obesity, smoking, and a family history of esophageal precancer (Barrett's esophagus) or cancer (esophageal adenocarcinoma).5,6
At least thirty million at-risk individuals with gastroesophageal disease (GERD), also known as chronic heartburn, are recommended for esophageal precancer testing by professional society clinical practice guidelines to prevent highly lethal esophageal cancer. Precancer detection is essential because esophageal cancer survival rates are poor, even when detected at Stage I.
The innovative Lucid Diagnostics lab is CLIA certified, CAP Accredited, and licensed by the New York State Department of Health.
MEET THE TEAM BEHIND THE TEST
Researchers, Physicians, Scientists, Innovators, Educators
EsoGuard was developed through the National Cancer Institute and arose from a collaboration among Case Western Reserve University faculty, including renowned cancer geneticists, a passionate gastroenterologist, and a dedicated pathologist.
Physician, Department of Gastroenterology, University Hospitals Cleveland Medical Center
Professor, Department of Medicine, School of Medicine
Case Western Reserve University
Physician, Department of Hematology and Oncology
Ingalls Professor of Cancer Genetics, Department of Medicine, School of Medicine
Case Western Reserve University
Assistant Professor, Case Comprehensive Cancer Center
Case Western Reserve University
Vice Chairman of Pathology, Clinical Affairs, Laboratory Director, University Hospitals Cleveland Medical Center
Professor, Department of Pathology, School of Medicine
Case Western Reserve University